Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced...

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Glutamate dehydrogenase 1 (GLUD1) is linked to cancer development.
• The role of GLUD1 in hepatocellular carcinoma (HCC) remains unclear.

Purpose of the Study:

• To investigate the expression and function of GLUD1 in HCC.
• To elucidate the molecular mechanisms underlying GLUD1 regulation in HCC.

Main Methods:

• Analysis of GLUD1 expression in HCC tumors and patient prognosis.
• Functional studies involving GLUD1 silencing in HCC cells.
• Investigation of molecular interactions including AKT, interleukin-32, LIM and SH3 protein 1 (LASP1), synoviolin (SYVN1), and hepatitis B virus X protein (HBX).

Main Results:

• GLUD1 expression is significantly reduced in HCC tumors, correlating with poor prognosis.
• GLUD1 silencing enhances HCC cell growth and migration.
• Upregulation of interleukin-32 via AKT activation contributes to GLUD1 silencing-induced hepatocarcinogenesis.
• LASP1 and SYVN1 mediate GLUD1 degradation through the ubiquitin-proteasome pathway.
• HBX in HBV-related HCC suppresses GLUD1 with LASP1 and SYVN1 involvement.

Conclusions:

• GLUD1 downregulation is associated with HCC progression.
• LASP1 and SYVN1 are key mediators of GLUD1 inhibition in HCC.
• Targeting GLUD1 or its regulatory pathways may offer therapeutic strategies for HCC, especially in HBV-associated cases.